MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
$6,558K
Free Cash flow
$15,416K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Maturity of available-for-sale s...
    • Accounts receivable, net
    • Accounts payable
    • Others
Negative Cash Flow Breakdown
    • Purchase of available-for-sale s...
    • Accrued expenses and other
    • Payment of debt
    • Others

Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Net (loss) income
-3,753 13,438 17,673 NaN
Depreciation and amortization
2,584 2,657 8,281 NaN
Stock-based compensation
1,896 1,617 5,327 NaN
Deferred income taxes
NaN 3,245 NaN NaN
Provision for credit loss recovery
0 0 -362 NaN
Loss on disposal of property and equipment
-6 0 -4 NaN
Loss on impairment of asset
NaN 0 NaN NaN
Accounts receivable, net
-27,325 20,089 1,192 NaN
Inventory, net
3,178 -3,961 752 NaN
Prepaid expenses and other
-116 718 -393 NaN
Other current assets
-60 26 139 NaN
Accounts payable
3,110 -1,330 877 NaN
Operating lease assets and liabilities, net
553 539 1,266 NaN
Accrued expenses and other
-11,694 12,875 279 NaN
Post-marketing commitment liability
-503 -672 -1,740 NaN
Net cash provided by operating activities
15,416 14,419 9,689 17,694
Purchase of property and equipment
0 -36 26 81
Purchase of available-for-sale securities
24,863 46,937 26,784 34,420
Maturity of available-for-sale securities
27,337 19,924 27,316 24,784
Purchase of intangible assets
NaN 0 NaN NaN
Net cash provided by investing activities
2,474 -26,977 506 -9,717
Net proceeds from shares issued under employee stock plans
NaN 0 0 130
Payment of debt
11,110 11,110 11,110 22,220
Payment of exit costs
222 222 222 444
Net cash used in financing activities
-11,332 -11,332 -11,332 -22,534
Net increase (decrease) in cash, cash equivalents and restricted cash
6,558 -23,890 -1,137 -14,557
Cash, cash equivalents and restricted cash, beginning of period
31,726 55,616 71,310 NaN
Cash, cash equivalents and restricted cash, end of period
38,284 31,726 55,616 NaN
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Accounts receivable, net-$27,325K Maturity ofavailable-for-sale securities$27,337K Accounts payable$3,110K Depreciation andamortization$2,584K Stock-based compensation$1,896K Prepaid expenses andother-$116K Other current assets-$60K Loss on disposal ofproperty and equipment-$6K Net cash provided byoperating activities$15,416K Net cash provided byinvesting activities$2,474K Canceled cashflow$19,681K Canceled cashflow$24,863K Net increase(decrease) in cash, cash...$6,558K Canceled cashflow$11,332K Accrued expenses andother-$11,694K Net (loss) income-$3,753K Inventory, net$3,178K Operating lease assets andliabilities, net$553K Post-marketing commitmentliability-$503K Purchase ofavailable-for-sale securities$24,863K Net cash used infinancing activities-$11,332K Payment of debt$11,110K Payment of exit costs$222K

PUMA BIOTECHNOLOGY, INC. (PBYI)

PUMA BIOTECHNOLOGY, INC. (PBYI)